1. Influence of sports on cortical excitability in patients with spinal cord injury: a TMS study.
- Author
-
Frey VN, Langthaler PB, Renz N, Zimmermann G, Höhn C, Schwenker K, Thomschewski A, Kunz AB, Höller Y, Nardone R, and Trinka E
- Abstract
Background: Patients with spinal cord injury (SCI) show abnormal cortical excitability that might be caused by deafferentation. We hypothesize a reduced short-interval intracortical inhibition preceding movement in patients with SCI compared with healthy participants. In addition, we expect that neuroplasticity induced by different types of sports can modulate intracortical inhibition during movement preparation in patients with SCI., Methods: We used a reaction test and paired-pulse transcranial magnetic stimulation to record cortical excitability, assessed by measuring amplitudes of motor-evoked potentials in preparation of movement. The participants were grouped as patients with SCI practicing wheelchair dancing ( n = 7), other sports ( n = 6), no sports ( n = 9), and healthy controls ( n = 24)., Results: There were neither significant differences between healthy participants and the patients nor between the different patient groups. A non-significant trend ( p = .238), showed that patients engaged in sports have a stronger increase in cortical excitability compared with patients of the non-sportive group, while the patients in the other sports group expressed the highest increase in cortical excitability., Conclusion: The small sample sizes limit the statistical power of the study, but the trending effect warrants further investigation of different sports on the neuroplasticity in patients with SCI. It is not clear how neuroplastic changes impact the sensorimotor output of the affected extremities in a patient. This needs to be followed up in further studies with a greater sample size., Competing Interests: ET has received consultancy fees from Arvelle Therapeutics, Argenx, Clexio, Celegene, UCB Pharma, Eisai, Epilog, Bial, Medtronic, Everpharma, Biogen, Takeda, Liva-Nova, Newbridge, Sunovion, GW Pharmaceuticals, and Marinus; speaker fees from Arvelle Therapeutics, Bial, Biogen, Böhringer Ingelheim, Eisai, Everpharma, GSK, GW Pharmaceuticals, Hikma, Liva-Nova, Newbridge, Novartis, Sanofi, Sandoz and UCB Pharma; research funding (directly, or to his institution) from GSK, Biogen, Eisai, Novartis, Red Bull, Bayer, and UCB Pharma outside the submitted work. ET receives Grants from Austrian Science Fund (FWF), Österreichische Nationalbank, and the European Union. ET is the CEO of Neuroconsult Ges.m.b.H. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer-review process and the final decision., (© 2024 Frey, Langthaler, Renz, Zimmermann, Höhn, Schwenker, Thomschewski, Kunz, Höller, Nardone and Trinka.)
- Published
- 2024
- Full Text
- View/download PDF